Deciphering the Pharmacological Mechanism of Huayu Jiedu Formula in Acute Cerebral Infarction by Ultra‐High‐Performance Liquid Chromatography‐Quadrupole‐Exactive‐Mass Spectrometry, Network Pharmacology, and Experimental Validation
Chemistry & Biodiversity · 2025
DOI: 10.1002/cbdv.202501114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Wuchaonan Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Cerebral Infarction. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Huayu Jiedu formula (HYJDF), a traditional Chinese herbal compound effective against acute cerebral infarction (ACI), lacks a defined mechanism of action. HYJDF's bioactive components were identified via ultra‐high‐performance liquid chromatography‐Quadrupole‐Exactive‐mass spectrometry (UHPLC‐QE‐MS). Network pharmacology integrated the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform database‐predicted ACI targets and multiple databases to construct herb‐component‐target networks (Cytoscape). Core targets were prioritized through protein‐protein interaction network analysis (STRING) and topological filtering (degree/closeness/betweenness centrality). Pathway enrichment (Kyoto Encyclopedia of Genes and Genomes [KEGG] Database for Annotation, Visualization, and Integrated Discovery) and molecular docking (AutoDock Vina) were performed. Key findings were validated in vivo using a middle cerebral artery occlusion rat model. UHPLC‐QE‐MS identified 1041 components; 229 were ACI‐relevant. Topological analysis revealed 29 core targets (e.g., TP53, STAT3, interleukin [IL]6, tumor necrosis factor [TNF], and Akt1). KEGG enrichment implicated the PI3K/Akt pathway. Molecular docking confirmed high‐affinity binding between HYJDF components (e.g., arachidonic acid and baicalein) and targets (Akt1 and IL6). In vivo, HYJDF treatment upregulated PI3K/Akt phosphorylation, suppressed neuroinflammation, and attenuated cerebral ischemic injury. HYJDF mediates therapeutic effects against ACI primarily by activating the PI3K/Akt signaling pathway and downregulating associated inflammatory factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, China.
- Hunan Province Key Laboratory of Cerebrovascular Disease Prevention and Treatment of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, China.
- School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China.
ORCID-Profile: Yihui Deng
Zitieren
APA
Liu, W., Li, D., Yu, Y., Yang, J., Chen, Y., & Deng, Y. (2025). Deciphering the Pharmacological Mechanism of Huayu Jiedu Formula in Acute Cerebral Infarction by Ultra‐High‐Performance Liquid Chromatography‐Quadrupole‐Exactive‐Mass Spectrometry, Network Pharmacology, and Experimental Validation. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202501114
Vancouver
Liu W, Li D, Yu Y, Yang J, Chen Y, Deng Y. Deciphering the Pharmacological Mechanism of Huayu Jiedu Formula in Acute Cerebral Infarction by Ultra‐High‐Performance Liquid Chromatography‐Quadrupole‐Exactive‐Mass Spectrometry, Network Pharmacology, and Experimental Validation. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202501114
BibTeX
@article{Liu2025,
author = {Liu, Wuchaonan and Li, Dingxiang and Yu, Yunfeng and Yang, Jingjing and Chen, Yanling and Deng, Yihui},
title = {Deciphering the Pharmacological Mechanism of Huayu Jiedu Formula in Acute Cerebral Infarction by Ultra‐High‐Performance Liquid Chromatography‐Quadrupole‐Exactive‐Mass Spectrometry, Network Pharmacology, and Experimental Validation},
journal = {Chemistry & Biodiversity},
year = {2025},
doi = {10.1002/cbdv.202501114}
}
EUVIMED